{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:44:57Z","timestamp":1778557497429,"version":"3.51.4"},"reference-count":43,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.3892\/ijo.2016.3367","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T13:02:47Z","timestamp":1454331767000},"page":"1399-1407","source":"Crossref","is-referenced-by-count":16,"title":["Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model"],"prefix":"10.3892","volume":"48","author":[{"given":"AMR S.","family":"ABU LILA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHIHIRO","family":"KATO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASAKAZU","family":"FUKUSHIMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHENG-LONG","family":"HUANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIROMI","family":"WADA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TATSUHIRO","family":"ISHIDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"key":"key20180107185111_b1-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bjc.2011.400","article-title":"Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: Molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin","volume":"105","author":"Giovannetti","year":"2011","journal-title":"Br J Cancer"},{"key":"key20180107185111_b2-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"e46091","DOI":"10.1371\/journal.pone.0046091","article-title":"Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool","volume":"7","author":"Ostroff","year":"2012","journal-title":"PLoS One"},{"key":"key20180107185111_b3-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2486\/indhealth.42.435","article-title":"Malignant pleural mesothelioma in parts of Japan in relationship to asbestos exposure","volume":"42","author":"Kishimoto","year":"2004","journal-title":"Ind Health"},{"key":"key20180107185111_b4-ijo-48-04-1399","first-page":"262","article-title":"Localized malignant mesothelioma of the pleura","volume":"13","author":"Takahashi","year":"2007","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"key20180107185111_b5-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6602307","article-title":"The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050","volume":"92","author":"Hodgson","year":"2005","journal-title":"Br J Cancer"},{"key":"key20180107185111_b6-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1179\/oeh.2003.9.3.249","article-title":"Asbestos-related morbidity in India","volume":"9","author":"Joshi","year":"2003","journal-title":"Int J Occup Environ Health"},{"key":"key20180107185111_b7-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/JTO.0b013e318031d05c","article-title":"Four-modality therapy in malignant pleural mesothelioma: A phase II study","volume":"2","author":"Lucchi","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"Suppl 5","key":"key20180107185111_b8-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdq173","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Stahel","year":"2010","journal-title":"Ann Oncol"},{"key":"key20180107185111_b9-ijo-48-04-1399","first-page":"222","article-title":"Advances in malignant pleural mesothelioma therapy: Targeting EphA2 a novel approach","volume":"2","author":"Nasreen","year":"2012","journal-title":"Am J Cancer Res"},{"key":"key20180107185111_b10-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/annonc\/mdi094","article-title":"Chemotherapy options and new advances in malignant pleural mesothelioma","volume":"16","author":"Steele","year":"2005","journal-title":"Ann Oncol"},{"key":"key20180107185111_b11-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1634\/theoncologist.12-7-850","article-title":"Multidisciplinary treatment of malignant pleural mesothelioma","volume":"12","author":"Ceresoli","year":"2007","journal-title":"Oncologist"},{"key":"key20180107185111_b12-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3816\/CLC.2010.n.005","article-title":"Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: A phase II study","volume":"11","author":"Katirtzoglou","year":"2010","journal-title":"Clin Lung Cancer"},{"key":"key20180107185111_b13-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JTO.0b013e31802f3813","article-title":"Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment","volume":"2","author":"Sorensen","year":"2007","journal-title":"J Thorac Oncol"},{"key":"key20180107185111_b14-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1634\/theoncologist.6-4-363","article-title":"Pemetrexed disodium: A novel antifolate clinically active against multiple solid tumors","volume":"6","author":"Hanauske","year":"2001","journal-title":"Oncologist"},{"issue":"Suppl 5","key":"key20180107185111_b15-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"v103","DOI":"10.1093\/annonc\/mdj962","article-title":"Pemetrexed and malignant pleural mesothelioma","volume":"17","author":"Marangolo","year":"2006","journal-title":"Ann Oncol"},{"key":"key20180107185111_b16-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107185111_b17-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1349-7006.2009.01358.x","article-title":"Significance of thymidylate synthase for resistance to pemetrexed in lung cancer","volume":"101","author":"Ozasa","year":"2010","journal-title":"Cancer Sci"},{"key":"key20180107185111_b18-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.canlet.2011.06.006","article-title":"Establishment of pemetrexed-resistant non-small cell lung cancer cell lines","volume":"309","author":"Zhang","year":"2011","journal-title":"Cancer Lett"},{"key":"key20180107185111_b19-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1124\/pr.55.4.1","article-title":"RNA interference in biology and medicine","volume":"55","author":"Milhavet","year":"2003","journal-title":"Pharmacol Rev"},{"key":"key20180107185111_b20-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/1471-2407-8-348","article-title":"Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma","volume":"8","author":"Shirasaki","year":"2008","journal-title":"BMC Cancer"},{"key":"key20180107185111_b21-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1741-7007-10-58","article-title":"RNAi in the regulation of mammalian viral infections","volume":"10","author":"Jeang","year":"2012","journal-title":"BMC Biol"},{"key":"key20180107185111_b22-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nature06179","article-title":"Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway","volume":"449","author":"John","year":"2007","journal-title":"Nature"},{"key":"key20180107185111_b23-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1038\/mt.2011.174","article-title":"A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA","volume":"19","author":"Nakamura","year":"2011","journal-title":"Mol Ther"},{"key":"key20180107185111_b24-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.pharmthera.2005.03.004","article-title":"RNA interference: From gene silencing to gene-specific therapeutics","volume":"107","author":"Leung","year":"2005","journal-title":"Pharmacol Ther"},{"key":"key20180107185111_b25-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ejpb.2012.04.010","article-title":"Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin","volume":"81","author":"Abu Lila","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"key20180107185111_b26-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0021-9258(18)70227-5","article-title":"Colorimetric assay methods for free and phosphorylated glyceric acids","volume":"234","author":"Bartlett","year":"1959","journal-title":"J Biol Chem"},{"key":"key20180107185111_b27-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jep.2008.01.017","article-title":"Study of the antitumor potential of Bidens pilosa (Asteraceae) used in Brazilian folk medicine","volume":"117","author":"Kviecinski","year":"2008","journal-title":"J Ethnopharmacol"},{"key":"key20180107185111_b28-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2009.02.023","article-title":"Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model","volume":"137","author":"Abu Lila","year":"2009","journal-title":"J Control Release"},{"key":"key20180107185111_b29-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cis.2006.05.026","article-title":"Nanoparticles for bioimaging","volume":"123\u2013126","author":"Sharma","year":"2006","journal-title":"Adv Colloid Interface Sci"},{"key":"key20180107185111_b30-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/bjc.2011.129","article-title":"Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer","volume":"104","author":"Takezawa","year":"2011","journal-title":"Br J Cancer"},{"key":"key20180107185111_b31-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ijc.11014","article-title":"New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction","volume":"104","author":"Shintani","year":"2003","journal-title":"Int J Cancer"},{"key":"key20180107185111_b32-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/cncr.21777","article-title":"Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung","volume":"106","author":"Hashimoto","year":"2006","journal-title":"Cancer"},{"key":"key20180107185111_b33-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/418244a","article-title":"RNA interference","volume":"418","author":"Hannon","year":"2002","journal-title":"Nature"},{"key":"key20180107185111_b34-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14728222.12.5.637","article-title":"Small interfering RNA therapy in cancer: Mechanism, potential targets, and clinical applications","volume":"12","author":"Huang","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"key20180107185111_b35-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nature11779","article-title":"Identification of small RNA pathway genes using patterns of phylogenetic conservation and divergence","volume":"493","author":"Tabach","year":"2013","journal-title":"Nature"},{"key":"key20180107185111_b36-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.biopha.2012.04.007","article-title":"Effect of short hairpin RNA-induced CXCR4 silence on ovarian cancer cell","volume":"66","author":"Chen","year":"2012","journal-title":"Biomed Pharmacother"},{"key":"key20180107185111_b37-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature07758","article-title":"The promises and pitfalls of RNA-interference-based therapeutics","volume":"457","author":"Castanotto","year":"2009","journal-title":"Nature"},{"key":"key20180107185111_b38-ijo-48-04-1399","first-page":"2011","article-title":"Synthetic pre-miRNA-based shRNA as potent RNAi triggers","volume":"131579","author":"Terasawa","year":"2011","journal-title":"J Nucleic Acids"},{"key":"key20180107185111_b39-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd3010","article-title":"Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application","volume":"9","author":"Jackson","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107185111_b40-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/ijc.25716","article-title":"Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma","volume":"129","author":"Iwahori","year":"2011","journal-title":"Int J Cancer"},{"key":"key20180107185111_b41-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: High rate of antitumor immune responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107185111_b42-ijo-48-04-1399","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1158\/1078-0432.CCR-05-0405","article-title":"Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase\/ganciclovir suicide gene therapy","volume":"11","author":"Sterman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180107185111_b43-ijo-48-04-1399","first-page":"319287","article-title":"Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapy","volume":"2012","author":"Storch","year":"2012","journal-title":"Chemother Res Pract"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2016.3367\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T22:18:06Z","timestamp":1654208286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2016.3367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,2,1]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.3892\/ijo.2016.3367"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2016.3367","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]}}}